PORTABLE SELF APPLYING DROWSINESS DETECTION DEVICE
Small Business Information
Advanced Biomedical Monitoring
10751 WILSHIRE BLVD, STE PH9, Los Angeles, CA, 90025
Name: KONSTANTINOVIC, ZORAN R
Phone: () -
Phone: () -
Phone: (310) 442-5212
AbstractDESCRIPTION (Adapted from applicant's abstract): The goal of this project is to design and develop a lightweight portable headset device capable of recording EEG in human subjects to provide feedback reflecting the onset of drowsiness during their normal daily activities. The Drowsiness Monitoring Device (DMD) will incorporate an existing hybrid amplifier design to acquire high quality ambulatory EEG signals. An optional battery powered solid state digital recorder will provide ambulatory EEG recordings for off-line data reduction and analysis. In Phase I, data collection from 20 subjects will be used to develop computer algorithms to reject artifact and identify EEG indices of drowsiness in real time. The amplifiers will be redesigned to reduce power consumption, and include on-line calibration and impedance monitoring and specifications will be outlined for digital signal processing hardware. Phase II will focus on constructing an easy to use headset device including: an electrode placement mechanism, automatic diagnostic software and an auditory feedback system triggered by the detection of drowsiness in the EEG in real time. The complete system will be validated on a cross section of normal ambulatory subjects in their work environments. The final product is intended to prevent accidents caused by individuals whose occupations require sustained periods of vigilance (e.g. pilots, truck drivers etc.) and to assist those suffering from sleep disorders. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 493 --PROJECT NUMBER......1 R43 NS35396-01A1 INVESTIGATOR NAME/ADDRESS FY 97 DEHAVEN-HUDKINS, DIANE L IRG/INTRAMURAL UNIT..ZRG1 ADOLOR CORPORATION AWARD AMOUNT......... $99,983 395 PHOENIXVILLE PIKE MALVERN, PA 19355 PERFORMING ORGANIZATION: ADOLOR CORPORATION TITLE IDENTIFICATION OF NOVEL LIGANDS FOR THE ORL-1 RECEPTOR ABSTRACT: (Investigator's Abstract): The goal of this application is to identify novel compounds which selectively interact with the opiate-like orphan receptor (ORL-1) for potential use as novel analgesics. The ORL-1 receptor is aprotein which shares 65 percent homology with known opiate receptors, but at present its physiological function is uncertain. Nociceptin or orphaning FQ is the endogenous ligand for the ORL-1 receptor, and they will use [3H]nociceptin and membranes from mammalian cells stably expressing the cloned human ORL-1 receptor to validate a binding assay for high throughput screening of various compound files. Compounds for testing will be peptides, peptidomimetics and nonpeptidic compounds obtained from commercial and proprietary sources. Potent and specific inhibitors of binding to the ORL-1 receptor will be used to characterize the physiological role(s) of ORL-1 receptors as an aid in the identification of potential therapeutic applications for agonists or antagonists. Specificity will be determined by evaluation of the active compounds in receptor binding assays using other cloned human opiate receptors available at Adolor. ORL-1- mediated changes in cAMP levels will show functional sequelae of the interaction with ORL-1 receptors at the cellular level and will define the nature of novel compounds as agonists or antagonists. Evaluation of nociceptin and putative ORL-1 agonists and antagonists in a battery of assays which measure analgesia and motor coordination will establish the role of nociceptin and the ORL-1 receptor in pain modulation. The discovery of compounds that bind to the ORL-1 site and function as agonists or antagonists will aid in the further elucidation of the physiological role of this binding site and its relevance to pain perception and central nervous system function. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 494 --PROJECT NUMBER......1 R43 NS35410-01A1 INVESTIGATOR NAME/ADDRESS FY 97 DE SOUZA, ERROL B IRG/INTRAMURAL UNIT..ZRG1 NEUROCRINE BIOSCIENCES INC AWARD AMOUNT......... $100,000 3050 SCIENCE PARK RD SAN DIEGO, CA 92121 PERFORMING ORGANIZATION: NEUROCRINE BIOSCIENCES, INC. TITLE CRF RECEPTOR ANTAGONISTS IN NEUROPROTECTION ABSTRACT: DESCRIPTION (Adapted from Investigator's Abstract): Corticotropin releasing factor (CRF) is a primary integrator of the stress response and there is evidence that CRF acts as a neurotransmitter or neuromodulator in the brain. The effects of CRF in the brain are mediated by two distinct receptors, CRF1 and CRF2. Activation of CRF receptors leads to an increase in neuronal excitability while administration of peptide CRF antagonists can result in reduced neuronal damage in models of focal and global ischaemia and following excitatory amino acid administration. Although peptide CRF antagonists appear to be neuroprotective, their therapeutic utility is limited by their short half-life and inability to cross the blood-brain barrier. This proposal will examine the neuroprotective ability of novel, non-peptide, CRF1 receptor antagonists following systemic administration of the antagonists. The specific aims are: 1) to screen four CRF1 receptor antagonist lead compounds for their efficacy as neuroprotective agents against excitatory amino acid-induced neurodegeneration; 2) to complete time course and dose-response studies of one lead compound, NBI 27914, in the middle cerebral artery occlusion (MCAo) model of cerebral ischaemia in order to determine optimal parameters for the further examination of the compounds examined in the first specific aim; and 3) to assess the effectiveness of the two most promising compounds from specific aim one in the MCAo model of cerebral ischaemia. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 495 --PROJECT NUMBER......9 R44 NS36100-02A1 INVESTIGATOR NAME/ADDRESS FY 97 SANDS, HOWARD IRG/INTRAMURAL UNIT..ZRG3 SPARTA PHARMACEUTICALS, CORP AWARD AMOUNT......... $421,443 111 ROCK ROAD HORSHAM, PA 19044-2310 PERFORMING ORGANIZATION: SPARTA PHARMACEUTICAL CORPORATION TITLE A NOVEL RECOMBINANT SERPIN FOR THE TREATMENT OF STROKE NO ABSTRACT ON FILE $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 496 --PROJECT NUMBER......1 R43 NS36106-01 INVESTIGATOR NAME/ADDRESS FY 97 DOYLE, TIMOTHY J IRG/INTRAMURAL UNIT..ZRG1 NEUROIMAGING, INC AWARD AMOUNT......... $99,964 9227 TWIN HILLS HOUSTON, TX 77031 PERFORMING ORGANIZATION: NEUROIMAGING, INC. TITLE NEUROLOGICAL DISEASES--NOVEL DIAGNOSTIC SOFTWARE ABSTRACT: Routine biopsy for managing patients with neurological diseases such as multiple sclerosis (MS), brain tumors, Alzheimer's disease, etc., is not a viable option. Quantitative magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (SI) noninvasively provide tissue morphometric and biochemical information, respectively. This information would be extremely valuable for an objective characterization of the disease state and would greatly help in patient management. However, at present, this powerful technology is not exploited to its fullest extent, except in highly specialized centers, since software that can be routinely used in a typical clinical setting does not exist. The purpose of this proposal is to develop an automatic quantitative MR analysis software package which is robust, user- friendly, and computationally efficient so that it can be routinely used in a typical clinical setting. The proposed software package will allow volume quantitation of white matter (WM), gray matter (GM), cerebrospinal fluid (CSF), lesions, tumors, edema, etc., through MRI and distributions of brain metabolites through SI. This software package will also provide an interface between MRI and SI for an anatomic- metabolic correlation. Such a correlation can be thought of as a "noninvasive biopsy." We will confine ourselves to the development of MRI analysis software during phase I. The necessary software will be developed on a workstation and tested on brain-stimulating phantoms. In phase II, the system will be refined for complete automation, and evaluated on human volunteers. In phase II, the development and evaluation of the software package for SI analysis will also be undertaken. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 497 --PROJECT NUMBER......1 R43 NS36119-01 INVESTIGATOR NAME/ADDRESS FY 97 HSIA, CARLETON J IRG/INTRAMURAL UNIT..ZRG3 SYNZYME TECHNOLOGIES INC AWARD AMOUNT......... $100,000 ONE TECHNOLOGY DRIVE IRVINE, CA 92618 PERFORMING ORGANIZATION: SYNZYME TECHNOLOGY, INC. TITLE NEUROPROTECTIVE REPERFUSION THERAPY WITH PNA ABSTRACT: This proposal describes the development of a novel agent for the treatment of stroke. The agent, polynitroxyl-albumin (PNA), is a potent antioxidant; the rationale for the therapy is that oxygen free radical formation in the vascular space initiates a cascade of toxic events leading to stroke injury. Preliminary results from middle cerebral artery occlusion (MCAO) studies in rodents have indicated that PNA protects against ischemic and reperfusion injury in the brain, that it reduces infarct volume following stroke, and that it may actually enhance cerebral perfusion via a vasodilator activity. PNA's protective activity is substantially greater than that of unmodified human serum albumin; PNA can therefore be thought of as a therapeutic colloid solution with antioxidant and vasodilator activities, or a 'neuroprotective therapeutic reperfusion agent'. The project will consist of studies on PNA's effects on cerebral hemodynamics and metabolism during stroke; diffusion- and perfusion-weighted magnetic resonance imaging studies of PNA~s effects on ischemic and reperfusion injury and cerebral blood flow; and studies to confirm that PNA reduces infarct volume following MCAO. If successful, this project will give an understanding of the mechanism of action of PNA, and lead to its complete preclinical development for stroke therapy in Phase II.
* information listed above is at the time of submission.